Season 11 · Episode 2
S11 Ep2: ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma
OncLive® On Air · OncLive® On Air
August 12, 202410m 9s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.